Alleviation of ER stress as a translational strategy to curb ocular viral infections
缓解内质网应激作为遏制眼部病毒感染的转化策略
基本信息
- 批准号:10392735
- 负责人:
- 金额:$ 108.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcyclovirAnimal ModelAntiviral AgentsAntiviral TherapyBehavioralBiological AvailabilityBlindnessCREB3 geneCaviaCell DeathCellsChemicalsClinicalComplementCorneaCyclic AMPDNA biosynthesisDataDevelopmentDoseDrug KineticsDrug resistanceDrug usageEndoplasmic ReticulumEnsureEye InfectionsFDA approvedFilmFormulationFrequenciesGoalsGuidelinesHealthHerpesviridaeHerpesviridae InfectionsHerpesvirus 1Herpetic KeratitisHomologous GeneHumanInfectionModalityModelingMolecular ChaperonesMonoclonal Antibody R24Mucous body substanceMusOralOrphan DrugsOryctolagus cuniculusPathologyPathway interactionsPeriodicityPermeabilityPharmaceutical PreparationsPharmacodynamicsPhasePoloxamersProcessProductionProteinsRNA InterferenceSafetyScientistSimplexvirusSodiumSodium phenylbutyrateTestingTherapeuticThymidine KinaseTimeTopical applicationTranslatingTranslationsUnited StatesUrea cycle disordersVP 16ViralViral Eye InfectionsViral ProteinsVirus DiseasesVirus ReplicationWorkanti-viral efficacycorneal epitheliumdosagedrug developmentefficacy studyendoplasmic reticulum stressexhaustionimprovedin vivointraperitonealmeetingsmouse modelmultidisciplinarynanoformulationnovel therapeuticsnucleoside analogocular surfacepharmacokinetics and pharmacodynamicspre-clinicalpreclinical studypreventresponsesafety studytopical antiviraltraittranscription factortranslational approachviral DNAviral resistance
项目摘要
Infection-associated blindness caused by herpesviruses is a leading cause of vision loss in the United States.
Frontline therapies include the use of nucleoside analogs such as acyclovir which inhibit the viral thymidine
kinase to restrict viral DNA replication. However, emergence of drug resistance and lack of strong corneal
bioavailability have made it an urgent priority to develop alternative therapeutics. We have recently discovered
a new mechanism through which herpesviruses, exemplified by herpes simplex virus type-1 (HSV-1),
propagate in the corneal epithelium. We have shown that endoplasmic reticulum (ER)-localized host protein
cyclic adenosine 3′,5′-monophosphate (cAMP) response element-binding protein 3 (CREB3) is essential to
HSV-1 replication. Our findings shift the current understanding that CREB3 is only a cellular homolog of HSV-1
VP16. We showed that it is an important pro-viral factor that can be exploited to generate novel therapeutics
against HSV infections. We for the first time showed that its modulation via a chemical chaperone 4-
phenylbutyrate sodium (Na-PBA), can alleviate, ER stress, reduce CREB3 expression and inhibit viral
replication. PBA is currently approved to treat urea cycle disorder. Our translational results are supported by
strong in vivo murine data that suggests antiviral efficacy and topical dosage safety of Na-PBA. Due to the high
sodium burden associated with Na-PBA administration, its unpalatability, and inability to penetrate sufficiently
through corneal epithelium upon topical administration, we have developed various sodium-free PBA
nanoformulations to overcome limitations associated with oral and topical delivery of Na-PBA. The purpose of
this R24 application is to generate preclinical data in two animal models that support an IND application for
repurposing PBA to treat ocular HSV infection. This will be achieved via 3 well thought, exhaustive specific
aims. In the first aim, we will evaluate dose-dependent pharmacokinetics, and safety of orally and topically
delivered Na-PBA solution and various sodium-free PBA nanoformulations. Furthermore, we will also
determine oral and topical, and oral antiviral efficacy of Na-PBA and sodium-free PBA nanoformulations in
murine models of ocular HSV-1 infection. The second aim will use the most effective oral and topical
formulation(s) and test their safety, PK, and efficacy in guinea pig and rabbit models of primary and reactivated
ocular HSV-1 infection. Finally aim 3, we will investigate the potential of Na-PBA and sodium-free PBA
formulations to synergize with existing antiviral therapies to determine their potential as an add-on modality to
the existing treatment. The latter is likely and significant since PBA is a rare drug that works via alleviating ER
stress and aiding the host cell’s response to viral infection, and thereby reducing the chance for emergence
of viral resistance. We have assembled a multidisciplinary team including scientists, clinicians, drug
development and translation experts who can help us navigate through requisite FDA guidelines. PBA has the
potential to become a safe and efficacious alternative to existing ocular antivirals very quickly.
由疱疹病毒引起的感染相关失明是美国视力丧失的主要原因。
一线疗法包括使用核苷类似物,例如抑制病毒胸苷的阿昔洛韦
限制病毒 DNA 复制的激酶。然而,耐药性的出现和角膜强度的缺乏
生物利用度使得开发替代疗法成为当务之急。我们最近发现
疱疹病毒(以 1 型单纯疱疹病毒 (HSV-1) 为代表)通过一种新机制,
在角膜上皮中繁殖。我们已经证明内质网(ER)定位的宿主蛋白
环腺苷 3′,5′-单磷酸 (cAMP) 反应元件结合蛋白 3 (CREB3) 对于
HSV-1 复制。我们的发现改变了目前的认识,即 CREB3 只是 HSV-1 的细胞同源物
副总裁16。我们证明它是一种重要的促病毒因子,可用于产生新的疗法
对抗 HSV 感染。我们首次表明它通过化学伴侣 4- 进行调节
苯丁酸钠(Na-PBA),可以缓解内质网应激,降低CREB3表达并抑制病毒
复制。 PBA 目前被批准用于治疗尿素循环障碍。我们的翻译结果得到以下支持
强有力的小鼠体内数据表明 Na-PBA 的抗病毒功效和局部剂量安全性。由于高
与 Na-PBA 给药相关的钠负荷、其难吃性和无法充分渗透
通过局部给药,通过角膜上皮,我们开发了各种无钠PBA
纳米制剂克服了与口服和局部给药 Na-PBA 相关的局限性。目的
该 R24 应用程序旨在在两种动物模型中生成临床前数据,以支持 IND 申请
重新利用 PBA 治疗眼部 HSV 感染。这将通过 3 个深思熟虑、详尽的具体措施来实现
目标。在第一个目标中,我们将评估剂量依赖性药代动力学以及口服和局部用药的安全性
提供Na-PBA溶液和各种无钠PBA纳米制剂。此外,我们还将
确定 Na-PBA 和无钠 PBA 纳米制剂的口服和局部以及口服抗病毒功效
眼部 HSV-1 感染的小鼠模型。第二个目标将使用最有效的口服和局部用药
制剂并在原发和再激活的豚鼠和兔模型中测试其安全性、PK 和功效
眼部 HSV-1 感染。最后目标 3,我们将研究 Na-PBA 和无钠 PBA 的潜力
与现有抗病毒疗法协同作用的制剂,以确定其作为附加疗法的潜力
现有的治疗方法。后者很可能而且意义重大,因为 PBA 是一种通过缓解 ER 发挥作用的稀有药物
应激并帮助宿主细胞对病毒感染做出反应,从而减少出现的机会
病毒抵抗力。我们组建了一支多学科团队,包括科学家、临床医生、药物
开发和翻译专家可以帮助我们了解必要的 FDA 指南。 PBA 具有
有潜力很快成为现有眼部抗病毒药物的安全有效替代品。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Abhijit A Date其他文献
Abhijit A Date的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Abhijit A Date', 18)}}的其他基金
Ionic Liquids of tenofovir prodrugs for improved oral bioavailability and antiviral efficacy
替诺福韦前药离子液体可提高口服生物利用度和抗病毒功效
- 批准号:
10699620 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Alleviation of ER stress as a translational strategy to curb ocular viral infections
缓解内质网应激作为遏制眼部病毒感染的转化策略
- 批准号:
10576905 - 财政年份:2022
- 资助金额:
$ 108.12万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 108.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




